Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

OP is considering switching from ketoconazole shampoo to piroctone olamine (PTO) due to scalp irritation. Users report mixed experiences, with some finding PTO less irritating and more soothing than ketoconazole.

Concerns about a potential ban on finasteride and dutasteride due to side effects, with users advocating for continued access and informed choice. Alternative treatments like pyrilutamide are also mentioned.

PP405 is a potential hair loss treatment showing promise, especially for men with severe balding. Some are hopeful it will be a game-changer for those who cannot tolerate finasteride or minoxidil, despite skepticism about the outcomes.

PP405 is a medicine, and Google Ventures is funding its development based on evidence from each phase, unlike their investment in Juicero, which was a trend-based gamble. Investing in medicine is a calculated risk, not reliant on being "cool."

PP405 is being discussed as a potential new approach to hair loss by targeting follicle stem cells, suggesting a different mechanism from existing treatments like finasteride and minoxidil. However, there is skepticism about whether it will lead to meaningful long-term outcomes or follow the pattern of previous treatments that showed promise but lacked consistent results.

Dutasteride capsules should not be bitten or opened due to their foul taste and potential caustic effects. Users shared experiences of accidentally biting capsules and the unpleasant taste, with some suggesting swallowing techniques to avoid this.

PP405 is discussed as a potential hair growth stimulant, possibly more effective than minoxidil, but not a cure for hair loss. There is skepticism about its ability to regrow "deadzones," and concerns about its impact on those with hair transplants.

There is an inconsistency between the molecular weight and formula listed on EveryChem's product page and the analytical PDFs for 3HP and PP30, suggesting a possible error in the product description. Concerns are raised about EveryChem's business practices and lack of transparency in testing and manufacturing.

PP405 shows potential for hair growth by increasing terminal hair and converting vellus hairs, but results are modest and more waiting is needed. It complements existing treatments like minoxidil and finasteride, but won't replace them.

PP405 may help with hair regrowth, especially when combined with minoxidil and finasteride, but its long-term effectiveness is unclear. Phase 3 trials are expected to begin soon, with results in a few years.

PP405 is advancing to Phase 2b trials, showing promise from Phase 2a. It may be available in 3-6 years, with trials using a topical gel.

The conversation discusses using black pepper to potentially enhance the absorption of dutasteride for hair loss treatment. It also humorously mentions other unconventional methods and ingredients like grapefruit juice and garlic.

Hair follicle stem cells remain in bald individuals, but progenitor cells do not, raising questions about hair regrowth claims by Pelage. PP405 is discussed as a potential treatment, with skepticism about its effectiveness compared to existing treatments like Minoxidil and Finasteride.

Latisse (bimatoprost) is discussed as a potential treatment for hair growth due to difficulty obtaining PGE2. Users also mention concerns about sourcing reliable products from China.

Breezula, a topical treatment, is anticipated to be available in the US by mid-2027 as a potential alternative to finasteride with fewer systemic side effects. There is ongoing debate about its effectiveness and some users report similar side effects to finasteride.

The conversation is about the effectiveness of Peptonix Peptide Infusion Hair Growth System for hair loss. The user is seeking feedback from others who have tried it, as there is limited data available.

The conversation is about using a topical finasteride solution without minoxidil to avoid side effects, with suggestions to use alternatives like a PG solvent or Stemox. There is also a mention of mixing finasteride with fisetin powder in the solvent.

The conversation humorously discusses hair regrowth using PP405, with jokes about side effects and secret hair transplants. The user claims no side effects except craving cheese.

The earliest pp405 might become available is likely between 2027 and 2030, with some users suggesting it could be as late as 2035. Current treatments mentioned include dutasteride and minoxidil.

The conversation discusses finding a PG-free solvent for dissolving RU58841 in the UK, with glycerin suggested as a potential alternative. Water is also mentioned as a possible option.

A user discusses using Alpecin Caffeine Liquid for scalp health and considers dissolving finasteride tablets into it for a DIY topical treatment. They inquire about potential absorption issues with this method.

PP405 is expected to be on the market between 2027 and 2030, with phase 3 trials starting in 2026. There is skepticism about its fast-tracking due to its cosmetic nature, and it may appear on the gray market sooner.

PP405 is moving to late-stage trials, showing potential for hair regrowth, with 31% of male patients experiencing a 20% increase in hair density. Veradermics is developing an oral minoxidil version, and there is interest in combining treatments for better results.

Amplifica is testing a compound called AMP-303 for hair loss, but it's not Scube3 or osteopontin. The timing for the results from the clinical trial is unknown.

People are discussing their reactions if PP405 fails in phase 3 trials, with some expressing skepticism and others holding onto hope for future treatments like GT20029 and Breezula. Many mention continuing with existing treatments like minoxidil and finasteride, while others express disappointment and consider alternative solutions.

France is considering reviewing finasteride and dutasteride due to concerns about their safety, but a ban in the EU is unlikely due to regulatory hurdles. Many users express frustration over the potential ban, emphasizing the effectiveness of finasteride for hair loss and criticizing the influence of anecdotal evidence on public health policy.

Pelage plans to release PP405 trial results at a medical meeting in early 2026, possibly during the AAD conference in March. There is speculation about whether new hair loss treatments or GTA 6 will be released first.

PP405 is progressing to Phase 2b trials, with results expected in late 2025 or early 2026, and potential Phase 3 trials in 2026. Some users experienced side effects from finasteride and are hopeful for PP405 as an alternative treatment.

GT20029 shows promise as a topical treatment for hair loss, potentially replacing finasteride for some due to its low systemic exposure and ability to degrade androgen receptors. However, skepticism remains about its long-term efficacy and availability, with some users expressing doubt about new treatments consistently failing to reach the market.

The user experienced temporary peach fuzz growth using a product with procapil and later tried minoxidil and finasteride without significant results. Their boyfriend has used minoxidil and finasteride consistently for over five years with sparse hair improvement.